Skip to main content

Advertisement

Table 4 Phase II studies of antiangiogenic therapy

From: Targeted therapies in breast cancer: are heart and vessels also being targeted?

Study Treatment Line of therapy Number of patients Hypertension (grade 3 or 4) (%) CHF NYHA class III or IV (%) Thrombotic events (grade 3 or 4) (%)
Miller et al. [89] Vandetanib monotherapy 2, 3 46 0 0 0
Boer et al. [90] Vandetanib + docetaxel versus vandetanib 1 64 0 0 0
Rugo et al. [91] Axitinib + docetaxel versus docetaxel 1 168 5 0 0
Taylor et al. [92] Pazopanib monotherapya 1, 2, 3 18 14 0 0
Moreno-Aspitia et al. [111] Sorafenib monotherapy 1, 2 23 0 0 0
Baselga et al. [86] Sorafenib + capecitabine versus capecitabine 1, 2 229 0 0 0
Isaascs et al. [87] Sorafenib + anastrozole versus anastrozolea 1, 2 35 11 0 0
Gradishar et al. [88] Sorafenib + paclitaxel versus paclitaxel 1 237 0 0 0
  1. aPreliminary results. CHF, congestive heart failure; NYHA, New York Heart Association.